NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 03/30/2020 11:07
Last Report Issued 11/14/2011 06:09

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 0013SP
Patient ID 0013SP
Chain 11003488
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 11003488

Received 11/14/2011 06:05

Sample ID 11003488-001
Matrix Serum or Plasma
Patient Name 0013SP
Patient ID 0013SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
0013SP Acamprosate, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Acamprosate	None Detected	ng/mL	50	

Synonym(s): Campral; N-acetylhomotaurine; calcium acetylhomotaurinate

Acamprosate is a synthetic psychotropic drug used in the treatment of alcohol dependence. It has been shown to reduce cumulative days drinking and alcohol-induced cravings. Upon ingestion, acamprosate immediately dissociates into N-acetyl homotaurine; this is the compound that is measured and reported. Steady-state acamprosate concentrations following 2 x 333 mg tablets three times daily ranged from 370 +/- 145 to 644 +/- 386 ng/mL and were achieved 3.5 +/- 0.5 to 9.0 +/- 1.9 hours after dose.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.